Résztvevőt keres itt: Egyesült Államok3. fázis
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
A legfontosabb adatok
- Ki végzi
- AstraZeneca
- Hol
- Amarillo, Annapolis, Atlanta, Baton Rouge, Birmingham, Boise, Bradenton, Brooklyn, Buffalo, Chapel Hill, Charlottesville, Chicago, Chula Vista, Cleveland, Colorado Springs, Columbia, Columbus, Corvallis, Dallas, Denver, Detroit, Durham, El Paso, Elmhurst, Evanston, Fort Wayne, Fresno, Gainesville, Green Bay, Greenville, Houston, Iowa City, Jacksonville, Kansas City, La Mesa, Lakeland, Los Angeles, Louisville, Miami, Milwaukee, Mobile, New Orleans, New York, Newport Beach, Oklahoma City, Philadelphia, Phoenix, Pittsburgh, Portland, Potsdam, Providence, Royal Oak, Saint Paul, Salt Lake City, Shreveport, Silver Spring, Sioux Falls, South Pasadena, Springfield, St Louis, St. Petersburg, Tampa, Toledo, Torrance, Tucson, Washington D.C., Winston-Salem és Worcester (Egyesült Államok)Mind a 68 helyszín megnézéseMég 38 másik országban, 308 helyszínen
- Állapot
- Toboroz
- Fázis
- 3. fázis
- Résztvevők
- 3527 fő, tervezett
- Kezdés
- 2022. dec. 13.
- Várható befejezés
- 2027. nov. 4.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- Tozorakimab
- Placebo
- A regiszteradat frissítve
- 2026. október 30.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 7 feltétel megnézéseKevesebb
Ki vehet részt
- Adult participants ≥ 18 years old at the time of signing the informed consent form
- Patients hospitalised with viral lung infection
- Hypoxaemia requiring treatment with supplemental O2; Hypoxaemia is defined as:; SpO2 ≤ 90% OR; SpO2 ≤ 92% AND one or both of the following:; Radiographic infiltrates by CXR/CT compatible with viral lung infection per investigator judgement; Use of accessory muscles of respiration or RR (respiratory rate) > 22
- Patient remains hypoxaemic at randomisation requiring treatment with supplemental oxygen
Ki nem vehet részt
- Known fungal or parasitic lung infection, aspiration lung infection, lung abscess, or evidence of septic shock. Bacterial co-infection is allowed, unless, in the opinion of the investigator, bacterial infection defines the severity of the participant's condition
- Hypoxaemia caused primarily by extrapulmonary insult or by lung injury of non-infective aetiology
- Ongoing IMV/ECMO at randomisation
Helyszínek itt: Egyesült Államok
Még 38 másik országban, 308 helyszínen
- Amarillo, TexasHospital not named in the registryToborzás még nem indult
- Annapolis, MarylandHospital not named in the registryRésztvevőt keres
- Atlanta, GeorgiaHospital not named in the registryNo longer taking part
- Baton Rouge, LouisianaHospital not named in the registryRésztvevőt keres
- Birmingham, AlabamaHospital not named in the registryToborzás még nem indult
- Boise, IdahoHospital not named in the registryRésztvevőt keres
- Bradenton, FloridaHospital not named in the registryNo longer taking part
- Brooklyn, New YorkHospital not named in the registryNo longer taking part
- Buffalo, New YorkHospital not named in the registryToborzás még nem indult
- Chapel Hill, North CarolinaHospital not named in the registryNo longer taking part
- Charlottesville, VirginiaHospital not named in the registryRésztvevőt keres
- Chicago, IllinoisHospital not named in the registryNo longer taking part
- Chula Vista, CaliforniaHospital not named in the registryNo longer taking part
- Cleveland, OhioHospital not named in the registryNo longer taking part
- Colorado Springs, ColoradoHospital not named in the registryRésztvevőt keres
- Columbia, MissouriHospital not named in the registryNo longer taking part
- Columbus, OhioHospital not named in the registryRésztvevőt keres
- Corvallis, OregonHospital not named in the registryNo longer taking part
- Dallas, TexasHospital not named in the registryNo longer taking part
- Denver, ColoradoHospital not named in the registryNo longer taking part
- Detroit, MichiganHospital not named in the registryRésztvevőt keres
- Durham, North CarolinaHospital not named in the registryToborzás még nem indult
- El Paso, TexasHospital not named in the registryRésztvevőt keres
- Elmhurst, IllinoisHospital not named in the registryNo longer taking part
- Evanston, IllinoisHospital not named in the registryRésztvevőt keres
- Fort Wayne, IndianaHospital not named in the registryNo longer taking part
- Fresno, CaliforniaHospital not named in the registryRésztvevőt keres
- Gainesville, FloridaHospital not named in the registryRésztvevőt keres
- Green Bay, WisconsinHospital not named in the registryNo longer taking part
- Greenville, South CarolinaHospital not named in the registryNo longer taking part
- Houston, TexasHospital not named in the registryNo longer taking part
- Iowa City, IowaHospital not named in the registryNo longer taking part
- Jacksonville, FloridaHospital not named in the registryRésztvevőt keres
- Kansas City, MissouriHospital not named in the registryNo longer taking part
- La Mesa, CaliforniaHospital not named in the registryNo longer taking part
- Lakeland, FloridaHospital not named in the registryRésztvevőt keres
- Los Angeles, CaliforniaHospital not named in the registryNo longer taking part
- Louisville, KentuckyHospital not named in the registryRésztvevőt keres
- Miami, FloridaHospital not named in the registryNo longer taking part
- Milwaukee, WisconsinHospital not named in the registryNo longer taking part
- Mobile, AlabamaHospital not named in the registryRésztvevőt keres
- New Orleans, LouisianaHospital not named in the registryNo longer taking part
- New YorkHospital not named in the registryNo longer taking part
- Newport Beach, CaliforniaHospital not named in the registryRésztvevőt keres
- Oklahoma City, OklahomaHospital not named in the registryRésztvevőt keres
- Philadelphia, PennsylvaniaHospital not named in the registryNo longer taking part
- Phoenix, ArizonaHospital not named in the registryNo longer taking part
- Pittsburgh, PennsylvaniaHospital not named in the registryToborzás még nem indult
- Portland, OregonHospital not named in the registryNo longer taking part
- Potsdam, New YorkHospital not named in the registryNo longer taking part
- Providence, Rhode IslandHospital not named in the registryNo longer taking part
- Royal Oak, MichiganHospital not named in the registryRésztvevőt keres
- Saint Paul, MinnesotaHospital not named in the registryRésztvevőt keres
- Salt Lake City, UtahHospital not named in the registryRésztvevőt keres
- Shreveport, LouisianaHospital not named in the registryNo longer taking part
- Silver Spring, MarylandHospital not named in the registryNo longer taking part
- Sioux Falls, South DakotaHospital not named in the registryNo longer taking part
- South Pasadena, CaliforniaHospital not named in the registryNo longer taking part
- Springfield, MissouriHospital not named in the registryNo longer taking part
- St Louis, MissouriHospital not named in the registryRésztvevőt keres
- St. Petersburg, FloridaHospital not named in the registryNo longer taking part
- Tampa, FloridaHospital not named in the registryRésztvevőt keres
- Toledo, OhioHospital not named in the registryRésztvevőt keres
- Torrance, CaliforniaHospital not named in the registryRésztvevőt keres
- Tucson, ArizonaHospital not named in the registryRésztvevőt keres
- Washington D.C., District of ColumbiaHospital not named in the registryRésztvevőt keres
- Winston-Salem, North CarolinaHospital not named in the registryRésztvevőt keres
- Worcester, MassachusettsHospital not named in the registryNo longer taking part
A vizsgálatról
Mit akar kideríteni a vizsgálat
The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.
A vizsgálat 2 csoportja
- TozorakimabA vizsgált kezelés
Approximately 2870 participants will be randomized in a 1:1 ratio. Arm 1 (n=approximately 1435) will receive a single dose of tozorakimab.
- PlaceboPlacebo, összehasonlításként
Approximately 2870 participants will be randomized in a 1:1 ratio. Arm 2 (n=approximately 1435) will receive matching placebo.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
- A regiszteradat frissítve
- 2026. október 30.